Levi & Korsinsky notifies investors that it has commenced an investigation into Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) concerning potential violations of the federal securities laws.
On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine. The trial, which targeted pain caused by a pinched nerve in the spine, showed no significant difference in pain reduction compared to a placebo. The company also announced plans to proceed with a Phase 3 trial for suzetrigine, a decision that has left some analysts questioning the rationale. One commentator stated on X "Vertex often gets the benefit of the doubt given its track record, but damn, this one is tough to reconcile." The company's announcements come mere days after insider transactions have been reported. Following this news, shares of Vertex fell 12% in morning trading on the same day.
If you suffered a loss on your Vertex Pharmaceuticals securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





